Rain Therapeutics Inc. (Rain) is a late-stage precision oncology company developing therapies that target oncogenic drivers. The Company’s lead product candidate, Milademetan (RAIN-32) is a small molecule, oral inhibitor of mouse double minute 2 (MDM2), which may be oncogenic in numerous cancers. RAIN-32 is being evaluated in an ongoing Phase III clinical trial in patients with LPS, as well as a Phase II tumor-agnostic basket trial in certain solid tumors (MANTRA-2). Rain is commencing a Phase II clinical trial of milademetan (MANTRA-3), for the treatment of patients with Merkel cell carcinoma. In addition to RAIN-32, the Company is also developing a preclinical program that is focused on inducing synthetic lethality in cancer cells by inhibiting RAD52. The MANTRA-3 trial is designed to evaluate the efficacy of milademetan, as a monotherapy in patients with MCC. Rain is also developing a preclinical program focused on targeting RAD52 in the deoxyribonucleic acid damage repair pathway.
During the most recent quarter, 1M shares were bought in insider trading.
Insider trading information report provided by Copyright © 2022. All rights reserved.
Reuters content is the intellectual property of Reuters. Any copying, republication or redistribution of Reuters content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters is not liable for any errors or delays in content, or for any actions taken in reliance on any content. Reuters, Reuters Logo and the Sphere Logo are trademarks and registered trademarks of the Reuters Group of companies around the world.
Data is provided for information purposes only and is not intended for trading purposes. Reuters shall not be liable for any errors or delay in the content, or for any action taken in reliance on any content. The RIC or Reuters Instrument Code set has been developed and maintained by Reuters and is the intellectual property of Reuters.